Drug details
Blincyto (blinatumomab for injection)
type of Bispecific T-Cell Engager (BiTE) Antibodies
Blincyto (blinatumomab) for injection is a bispecific CD19-directed CD3 T- cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- nausea,
- vomiting,
- diarrhea,
- fever,
- skin rash,
- easy bruising,
- unusual bleeding,
- pale skin,
- lightheadedness,
- shortness of breath,
- cold hands and feet,
- confusion,
- chills,
- body aches,
- tiredness,
- fluttering in your chest,
- seizure,
- constipation,
- headache,
- wheezing,
- weakness,
- muscle weakness,
- mouth sores,
- muscle cramps,
- loss of consciousness,
- irregular heartbeats,
- slurred speech,
- fast heart rate,
- skin sores,
- increased thirst or urination,
- decreased urination, and
- tingling in your hands and feet or around your mouth
- muscle pain,
- problems with your balance,
- severe pain in your upper stomach spreading to your back,
- leg cramps,
- numbness or tingling,
- limp feeling,
- fast or slow heartrate,
The following drugs are related to Blincyto, either as a replacement or used together:
- Campath (alemtuzumab)
- Scemblix (asciminib tablets)
- Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) injection)
- Symbenda (bendamustine hydrochloride)
- Busulfex (busulfan)
- Cytoxan (cyclophosphamide)
- Epkinly (epcoritamab-bysp injection)
- Nivestym (filgrastim-aafi injection)
- Fludara (fludarabine)
- Gleevec (imatinib mesylate)
- Jakafi (ruxolitinib)
- Jaypirca (pirtobrutinib tablets)
- Lumoxiti (moxetumomab pasudotox-tdfk for injection)
- Tasigna Capsules (nilotinib capsules)
- Oncaspar (pegaspargase)
- Vanflyta (quizartinib tablets)
- Vumon (teniposide)